On November 9, the FDA approved Bayer’s Sunharbo (asundexian) to reduce the risk of a second stroke in adults after a mild-to-moderate noncardioembolic ischemic stroke or high-risk TIA. The FDA said it is the first Factor XIa inhibitor approved for this use. That is a genuine scientific milestone. Whether it moves the needle for shareholders is a more complicated question.
The approval rests on the OCEANIC-STROKE Phase 3 trial. In the New England Journal of Medicine paper on the study, 12,327 adults were randomized to Sunharbo or placebo within 72 hours of symptom onset, both on top of antiplatelet therapy. Sunharbo reduced ischemic stroke risk by 26% over a median follow-up of 19 months. Major bleeding was reported as not increased versus placebo in the overall trial population.
Bayer has said it expects Sunharbo to begin shipping in the U.S. in mid-to-late November 2026, while regulatory reviews remain underway in Europe and Japan.
The Hole Sunharbo Has to Fill
The approval arrives precisely when Bayer needs it most, and that context matters for investors. Xarelto inhibits a different clotting protein and has faced a sales decline due to generic competition. In Bayer’s H1 2026 reporting, Xarelto sales were €738 million over the first six months of 2026, down about 43% from the same period a year prior. The drug that once generated more than €4 billion in annual global sales is now a fraction of itself.
Meanwhile, Bayer has told investors to expect litigation-related payouts of around €5 billion in 2026, which it has said could push free cash flow into a deeply negative range. In Bayer’s third-quarter 2026 reporting, the company posted a net loss of €672 million and negative free cash flow of €293 million, with net financial debt at about €31.1 billion at the end of September. This is the financial reality Sunharbo is launching into.
The Commercial Math
Peak sales estimates for Sunharbo span a wide range. Analysts have suggested Sunharbo could eventually reach around €3 billion in annual sales, while Bayer’s public commentary has pointed to a more modest figure around €1 billion after the drug’s atrial-fibrillation program, OCEANIC-AF, was stopped early in November 2023. That AF failure is the reason Sunharbo’s ceiling is contested.
Bayer has said the list price will be $748.50 for a 30-day supply of Sunharbo 50 mg tablets. At that price, broad uptake depends heavily on insurance coverage and physician adoption, neither of which is guaranteed at launch. The drug also sets the bar for the next competitor: Bristol Myers Squibb and Johnson & Johnson’s milvexian is being tested in a very similar post-stroke or high-risk TIA population, with enrollment around 12,500 and primary completion listed for October 2026.
What Long-Term Investors Should Watch
Bayer’s turnaround is real but uneven. In its third-quarter 2026 update, the company raised its 2026 adjusted EBITDA forecast to €9.8 billion to €10.3 billion and improved its free cash flow outlook by €1 billion.
Litigation risks may be easing at the margin. Bayer has pointed to a favorable U.S. Supreme Court ruling in the Roundup case Monsanto v. Durnell, and the company still faces ongoing legal and settlement-related milestones. Sunharbo adds a third leg to that recovery alongside newer drugs Nubeqa and Kerendia.
The enduring lesson here is one investors encounter repeatedly in large-cap pharma: a first-in-class approval is a beginning, not a resolution. Sunharbo is the right drug at the right time clinically. But the gap between a compelling Phase 3 result and a transformed income statement is measured in years of commercial execution, pricing negotiations, and competitive pressure. For Bayer, the question was never whether this drug worked. It was always whether a company still carrying about €31 billion in net debt and billions in annual litigation costs can convert a stroke-prevention breakthrough into a durable wealth-building moment for its shareholders. The answer will take longer than a single approval to write.